News

A massive new study of insomnia has shown it is partly heritable, and has also identified strong associations with conditions like type 2 diabetes.

Researchers are making strides in understanding the disease mechanism of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. They recently found that ubiquitin eliminates droplets of Ubiquilin-2 (UBQLN2) in solution. The discovery is noteworthy because UBQLN2 is a protein-encoding gene, mutations to which cause ALS and various types of dementia.

The proteins are linked to diabetic retinopathy, a major cause of visual impairment and blindness in working age people.

Lightning and volcanos both produce glass, and humans have been making glass from silicon dioxide since prehistory. Industrialization brought us boron-based glasses, polymer glasses and metallic glasses, but now an international team of researchers has developed a new family of glass based on metals and organic compounds that stacks up to the original silica in glass-forming ability.

Your cold heart or caring nature may actually be down to your genes, a new study suggests.

During some kinds of blood donations, such as platelet donation, you get most of the blood back. Researchers have been able to use leftover blood donor cells to gain crucial insights into how natural killer cells circulating in the human body differ from those typically studied in the lab.

Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.

A new study indicates that the kinds of microbes living in the gut influence the severity and recurrence of parasitic worm infections in developing countries. The findings suggest that manipulating the gut’s microbial communities may protect against intestinal parasites, which affect more than 1 billion people worldwide.

Using artificial intelligence and bioinformatics, researchers can create a two-dimensional mapping that can read test results, creating an Instagram of millions of blood cells. "It's an easy way to look at a complex response such as one you would find during immunotherapy."

Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.